Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise.
Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals discusses the appointment of John K. Jenkins, MD to its Board of Directors and the upcoming data from open-label extensions (OLEs) of its systemic sclerosis (SSc) and dermatomyositis (DM) Phase 2 studies which will be presented at the Annual European Congress of Rheumatology.
Before joining Corbus, Dr. Jenkins was Director of the Office of New Drugs (OND) at U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017, Dr. Jenkins was responsible for more than 1,000 agency employees and 19 product review divisions. During that time, he oversaw the review of thousands of new drug applications and biological licensing applications as well as the approval of more than 400 new molecular entities.
Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
